연구성과로 돌아가기

2025 연구자 정보 (483 / 657)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, Yoo Min
(Lee, YM) ⓘ 		Soonchunhyang Univ, Coll Med, Dept Pediat, Bucheon Hosp, Bucheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 35.9] Association of antinuclear antibody positivity with liver disease severity in pediatric metabolic dysfunction-associated steatotic liver disease ⓘ SCIE ⓘ 35.9 PEDIATRICS ⓘ ks200546@kosinmed.or.kr; ⓘ
Lee, Yoon-Jo
(Lee, YJ) ⓘ 		제1저자 Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, 7 Jukheon Gil, Gangneung Si 25457, Gangwon Do, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 35.9] The Application of L-Serine-Incorporated Gelatin Sponge into the Calvarial Defect of the Ovariectomized Rats ⓘ SCIE ⓘ 35.9 CELL & TISSUE ENGINEERING;ENGINEERING, BIOMEDICAL ⓘ kimsg@gwnu.ac.kr; ⓘ
Oh, Ji-Hyeon
(Oh, JH) ⓘ 		Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, 7 Jukheon Gil, Gangneung Si 25457, Gangwon Do, South Korea ⓘ
ⓘ 		0000-0002-6050-7175
Oh, Ji Hyeon ⓘ 		[JCR상위 35.9] The Application of L-Serine-Incorporated Gelatin Sponge into the Calvarial Defect of the Ovariectomized Rats ⓘ SCIE ⓘ 35.9 CELL & TISSUE ENGINEERING;ENGINEERING, BIOMEDICAL ⓘ kimsg@gwnu.ac.kr; ⓘ
Suh, Hyo Rim
(Suh, HR) ⓘ 		Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 35.9] Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B ⓘ SCIE ⓘ 35.9 PEDIATRICS ⓘ bhchoi@knu.ac.kr; ⓘ
Jeong, Yoon Young
(Jeong, YY) ⓘ 		Catholic Univ Daegu, Sch Med, Dept Obstet & Gynecol, 33 Duryugongwon ro 17 gil, Daegu 42472, South Korea
Daegu Catholic Univ, Sch Med, Dept Obstet & Gynecol, Daegu 42472, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.0] Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion
[JCR상위 22.4] Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib ⓘ 		SCIE ⓘ 22.4 ONCOLOGY
BIOCHEMISTRY & MOLECULAR BIOLOGY;CHEMISTRY, MULTIDISCIPLINARY ⓘ 		medgirl87@naver.com; gochong@knu.ac.kr;
xmas84@gmail.com; pathosjlee@cu.ac.kr; khseol@cu.ac.kr; nning@cu.ac.kr; jchoi@khu.ac.kr; bchoi@cu.ac.kr; medgirl1231@cu.ac.kr; drcys@cu.ac.kr; ⓘ
Kim, Jong Mi
(Kim, JM) ⓘ 		Kyungpook Natl Univ, Sch Med, Dept Obstet & Gynecol, 130 Dongdeok Ro, Daegu 41944, South Korea
Kyungpook Natl Univ, Chilgok Hosp, Dept Obstet & Gynecol, 807 Hoguk Ro, Daegu 41404, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.0] Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion ⓘ SCIE ⓘ 36.0 ONCOLOGY ⓘ medgirl87@naver.com; gochong@knu.ac.kr; ⓘ
Ryu, Jung Min
(Ryu, JM) ⓘ 		교신저자 Catholic Univ Daegu, Sch Med, Dept Obstet & Gynecol, 33 Duryugongwon ro 17 gil, Daegu 42472, South Korea
Daegu Catholic Univ, Sch Med, Dept Obstet & Gynecol, Daegu 42472, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.0] Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion
[JCR상위 22.4] Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib ⓘ 		SCIE ⓘ 22.4 ONCOLOGY
BIOCHEMISTRY & MOLECULAR BIOLOGY;CHEMISTRY, MULTIDISCIPLINARY ⓘ 		medgirl87@naver.com; gochong@knu.ac.kr;
xmas84@gmail.com; pathosjlee@cu.ac.kr; khseol@cu.ac.kr; nning@cu.ac.kr; jchoi@khu.ac.kr; bchoi@cu.ac.kr; medgirl1231@cu.ac.kr; drcys@cu.ac.kr; ⓘ
Yoon, Hee Yeun
(Yoon, HY) ⓘ 		제1저자 Kyungpook Natl Univ, Sch Med, Dept Obstet & Gynecol, 130 Dongdeok Ro, Daegu 41944, South Korea
Kyungpook Natl Univ, Chilgok Hosp, Dept Obstet & Gynecol, 807 Hoguk Ro, Daegu 41404, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.0] Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion ⓘ SCIE ⓘ 36.0 ONCOLOGY ⓘ medgirl87@naver.com; gochong@knu.ac.kr; ⓘ
Ahn, Ari
(Ahn, A) ⓘ 		Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Lab Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Chang, Yoon Hwan
(Chang, YH) ⓘ 		Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul Natl Univ Hosp, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Cho, Hee jeong
(Cho, HJ) ⓘ 		Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Cho, Hyungwoo
(Cho, H) ⓘ 		Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Cho, Jinhyun
(Cho, J) ⓘ 		Inha Univ, Inha Univ Hosp, Dept Internal Med, Div Hematol Oncol,Sch Med, Incheon 22332, South Korea
Inha Univ, Inha Univ Hosp, Dept Internal Med, Div Hematol Oncol,Sch Med, Incheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Choi, Jong Han
(Choi, JH) ⓘ 		Konkuk Univ, Dept Endocrine & Metab Med, Med Ctr, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025) ⓘ 		ESCI ⓘ 36.2 HEMATOLOGY ⓘ kihyunkimk@gmail.com; ⓘ
Choi, Yoon Seok
(Choi, YS) ⓘ 		Korea Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
Catholic Univ Daegu, Sch Med, Dept Obstet & Gynecol, 33 Duryugongwon ro 17 gil, Daegu 42472, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025)
[JCR상위 36.0] Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion ⓘ 		ESCI
SCIE ⓘ 		36.0 HEMATOLOGY
ONCOLOGY ⓘ 		kihyunkimk@gmail.com;
medgirl87@naver.com; gochong@knu.ac.kr; ⓘ
페이지 이동: